Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 27, 2025
VIVUS Announces QSYMIA® Now Available at Costco Pharmacies Nationwide
GlobeNewswire
·
May 27, 2025
— Expanded retail access aims to enhance overweight or obesity treatment accessibility CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that …
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
GlobeNewswire
·
May 27, 2025
Hamilton, May 27, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd. (“Altamira” or the …
HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC
GlobeNewswire
·
May 27, 2025
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the successful completion of the dose escalation portion of its …
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
GlobeNewswire
·
May 27, 2025
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under …
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders
GlobeNewswire
·
May 27, 2025
Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or moderate Parkinson’s disease (PD) through 18 months post-gene transfer Non-motor assessments …
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), …
Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease
GlobeNewswire
·
May 27, 2025
Results shared during a R…
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
GlobeNewswire
·
May 27, 2025
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire
·
May 27, 2025
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “ …
Strongline returns to market, signs deal with QLog to ensure leading staff duress offering is available to health systems around the country
GlobeNewswire
·
May 27, 2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Commure announced today a strategic partnership and licensing agreement with QLog, a leading Israeli innovator in real-time location systems (RTLS) and Bluetooth Low Energy (BLE) technologies for healthcare. …
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO …
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
May 27, 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’ …
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
May 27, 2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewswire
·
May 27, 2025
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery …
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
GlobeNewswire
·
May 27, 2025
ROSCREA, Ireland and FREIBURG, Germany, May 27, 2025 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) …
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the …
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual …
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship …
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 27, 2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …